Article Text

Download PDFPDF
M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease
  1. MP Cañadell1,2,
  2. D Moreno-Delgado2,3,
  3. M Rodríguez-Ruiz2,3,
  4. E Moreno2,3,
  5. J Botta2,3,
  6. P Gasperini2,3,4,
  7. A Cordomí5,
  8. LA Howell4,
  9. G Navarro2,3,
  10. V Casadó2,3,
  11. S Ferré5,
  12. M Guzmán2,6,
  13. L Pardo7,
  14. J Alberch1,2,
  15. EI Canela2,3,
  16. C Lluís2,3,
  17. P J McCormick2,3,4,
  18. S Ginés1,2
  1. 1Department of Cellular Biology, Immunology and Neuroscience, Faculty of Medicine, University of Barcelona, Spain
  2. 2Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas
  3. 3Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Spain
  4. 4School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ
  5. 5National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224 Maryland, USA
  6. 6Department of Biochemistry and Molecular Biology I, School of Biology, Computense University of Madrid, Spain
  7. 7Computational Medicine Laboratory, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain


In the early stages of Huntington’s disease (HD) there is an excess of dopamine production and an over-activation of dopamine D1 receptors (D1R) that can produce not only an imbalance in dopaminergic neurotransmission but can also directly lead to signalling cascades that induce cell death. However, simply blocking of D1R has important drawbacks as it disrupts several physiological functions. Importantly, many of these G-protein coupled receptors (GPCRs) may interact and form the so called heteromers. These receptor complexes confer novel functions and have been proposed as excellent candidates to modulate receptor signalling. Here we propose a new and provocative strategy to reduce the D1R over-activation effects in HD by targeting the recently described receptor complexes of D1R and the histamine receptors H3 (H3R). We show the expression of D1R-H3R heteromers in a HD model of striatal neuronal progenitor cells and in different brain areas of mouse models of HD in the early but not in the late stages of the disease as well as in human control subjects and in grade 2 HD patients but not in grade 3 or 4 HD patients. Upon co-activation of D1R-H3R heteromers, H3R ligands act as a “molecular brake” for D1R signalling. D1R-induced cell death in cells and in brain slices and the signalling cascades responsible for this death are reduced by H3R ligands targeting D1R-H3R heteromers. Chronic treatment of pre-symptomatic HD mice with an H3R antagonist can restore both motor learning and spatial and recognition memory deficits of these animals and inhibits the loss of heteromer expression at more advanced diseases stages. Overall, these results demonstrate that D1R-H3R heteromers play a pivotal role in controlling dopaminergic neurotransmission and indicate that D1R-H3R heteromers can be a new target for treating HD in the pre-symptomatic stages of the disease.

  • GPCRs
  • dopamine
  • cognition and neurodegeneration

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.